Introgen Therapeutics About
Introgen Introgen Therapeutics (NASDAQ®: INGN) is a biopharmaceutical
company focused on the discovery, development and commercialization of molecular
therapies for the treatment of cancer and other serious diseases.Introgen uses
non-integrating gene agents. These agents are designed to increase production
of normal cancer-fighting proteins that act to overpower cancerous cells.
The Company has treated hundreds of patients with thousands of doses of its tumor
suppressor lead product candidate --ADVEXIN®--. Introgen's second
tumor suppressor product candidate, INGN 241, is in Phase 1-2 clinical
development and its third product candidate, INGN 225, a tumor vaccine,
is also in Phase 1-2 clinical development. Introgen's clinical trials evaluate
its products both alone and in combination with conventional treatments such as
chemotherapy,
radiation,
and surgery. With the limited efficacy and debilitating toxic effects
of conventional cancer treatments, Introgen's low-toxicity approach to cancer
treatment has drawn global interest from oncologists. ADVEXIN -- Cancer INGN
241--tumor suppressor product candidate, INGN 225 --
tumor vaccine More
on Introgen